Your new post is loading...
Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumors epigenetic signature.
Hematology Oncology | CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma multiforme, small cell lung cancer and ovarian cancer.Aldoxorubicin is a modified version of the chemotherapeutic agent doxorubicin, combined with a novel single-molecule linker that binds directly and specifically to circulating albumin.
This is a free case-based activity that includes discussion of a 20 year old male patient with a glioblastoma, presenting with his first relapse after radiation therapy. Along with the patient case, there is a discussion board on ASCO Connection, where users can post comments/questions to each other and to the faculty.
Moderate radiation therapy dose escalation above 60 Gy with concurrent TMZ does not seem to improve clinical outcomes for patients with GBM.
In comparison to normal brain tissue, glioblastomas exhibit significantly increased glucose uptake. Brain edema is a common complication during adjuvant chemoradiotherapy, leading to a requirement for glucocorticoid treatment. Glucocorticoid treatment frequently causes considerable deregulation of blood glucose levels. Therefore, episodes of hyperglycemia may contribute to radio- and/or chemoresistance.
The authors report the current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United States 2006 to 2010 as well as demonstrate and discuss trends in incidence and survival. They also provide a concise review on molecular markers in GBM that have helped distinguish biologically similar subtypes of GBM and have prognostic and predictive value.
Jack L. Leonard, PhD, received a $250,000 grant from Hyundai Hope on Wheels and Worcester-area Hyundai dealers to explore a tumor suppressing pathway that arrests growth and initiates programmed cell death in glioblastoma tumor cells.
Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has remained marginal and GBM is still universally fatal with short survival times after initial diagnosis. Much research is focused on finding new therapeutics for GBM and immune based approaches have shown great promise. The detection of cytomegalovirus (CMV) antigens in malignant cells has suggested that treatment strategies based on immunological intervention, such as adoptive transfer of antiviral T cells or vaccination with viral epitopes, could be exploited as cancer therapy.
The authors aim to investigate the effect of immunotherapy advances for glioblastoma. They conclude that the potential of complementary combinatorial immunotherapeutic regimens is highly exciting and warrants expedited investigation.
Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide.
In the setting of primary malignant brain tumors, first-line chemotherapy is often accompanied by lymphopenic immunologic deficiency. Although perhaps counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate and enhance antitumor immunotherapy. We discuss here our preclinical and clinical experiences with immunotherapy for glioblastoma, the most common and lethal primary malignant brain tumor, as well as the use of im
Glioblastoma is a tumor that forms from supportive tissue of the brain and spinal cord. Learn about glioblastoma and find information on how we support and care for adults with glioblastoma before, during, and after treatment.
This review discusses some of the principal genetic and epigenetic aberrations found in GBM that appear promising for targeted therapies now and in the near future, and it offers suggestions for future directions concerning the rather disappointing results of clinical trials to date.
The unknown of an aggressive and horrible disease...... We see certain issues that are present, but with no definitive timeline, everyday seems like I'm holding my breathe indefinitely, always ready for the unknown....but then the next day everything is ok. Just to wonder if he is really sick at all....this disease really runs a person through the mud.
The U.S. patient registry dataset or PRiDe includes data from every recurrent glioblastoma patient treated with the NovoTTF-100A System from October 2011 through November 2013 at 91 leading oncology centers in the United States (n=457).
Olaptesed pegol is a PEGylated mirror-image (L-) oligonucleotide that binds and neutralizes the chemokine CXCL12/SDF-1, preventing interaction with its receptors CXCR4 & CXCR7. The CXCL12/CXCR4/CXCR7 pathway directly affects tumor progression by controlling cancer cell survival, proliferation and migration, and also has indirect effects through angiogenesis and recruitment of immune cells.
U-M doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer.
The FDA has granted Orphan Drug designation to olaptesed pegol NOXA12 NOXXON Pharma for the treatment of glioblastoma in conjunction with radiotherapy.
Glioblastoma is an aggressive tumor with heterogeneous molecular features and complex host interactions, many of which are amenable to therapeutic intervention. Meaningful treatment advances will depend on identifying agents that target mechanistic vulnerabilities that are relevant to specific subgroups of patients; increasing patient enrollment into clinical trials is essential to accelerate the development of patient-tailored treatments.
Results from a Phase 1 study of ABT-414, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody drug conjugate, in patients with newly diagnosed glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor, will also be presented during an oral presentation.
Data being presented include results from a Phase 2 study evaluating the safety and efficacy of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, in combination with two broad-acting chemotherapeutic medicines in patients with non-small cell lung cancer (NSCLC).
A new PARP Inhibitor
About ABT-767
ABT-767 is an investigational poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor being evaluated in multiple tumor types. PARP is a naturally-occurring enzyme in the body that repairs damage to DNA, and in certain types of cancers, repairs cancer cells. ABT-767 is currently being investigated in an ongoing Phase I clinical trial in patients with a variety of solid tumors. ABT-767 is an investigational compound and its efficacy and safety have not been established by the FDA.
In this paper, we report two cases of long-term progression-free survival in patients with glioblastoma undergoing FGR using of 5–aminolevulinic acid (5-ALA-FGR) at the University Hospitals-Case Medical Center.
Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM: in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products.
During the second and third quarters of 2014, ImmunoCellular conducted discussions with regulatory authorities in the US and on the national level in Europe concerning the rationale, design and protocol of a phase III program for ICT-107 in newly diagnosed GBM.
